| NCT ID | NCT07015151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Lung Cancer Prevention |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,312 participants |
| Start Date | 2025-06-12 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,312 participants in total. It began in 2025-06-12 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. A national pilot program (IMPULSION) will be launched in 2025. Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units. The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.
Eligibility Criteria
Inclusion Criteria \* : * Persons aged over 50 and under 75 (74 years of age or older). * Active smokers or former smokers who quit less than 15 years ago. * Persons whose consumption is estimated at 20 packs/year or more, down to ≥15 cigarettes/day for a duration of consumption of ≥25 years and up to ≥10 cigarettes/day for ≥30 years, which takes into account the predominance of duration of consumption over quantity consumed in the risk of lung cancer. A pack-year corresponds to the consumption of one pack of 20 manufactured cigarettes per day for one year. A multiplier coefficient will be taken into account depending on the mode of consumption: Rolled cigarettes: 2; Cigarillos: 3; Cigars: 4; Pipes: 2.5; Hookahs: 25. * Persons affiliated with social security. - Person having signed their consent to participate in the study after having received full information about it, including the risks associated with participation. * Exclusion Criteria \* : * Individuals with severe comorbidities contraindicating lung cancer investigations and/or treatment (including surgery or stereotactic radiotherapy); * Individuals with impaired general condition (PS 2 and above); * Individuals with dyspnea at rest (mMRC4); * Individuals with a history of cancer undergoing active surveillance by chest computed tomography (CT or PET scan); personal history of lung cancer (lifetime); * Individuals with symptoms suggestive of lung cancer (hemoptysis, unexplained weight loss, recent onset or change in respiratory symptoms, etc.); * Individuals refusing to participate in the study * Individuals withdrawing their consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07015151 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Lung Cancer Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07015151 currently recruiting?
Yes, NCT07015151 is actively recruiting participants. Contact the research team at sebastien.couraud@chu-lyon.fr for enrollment information.
Where is the NCT07015151 trial being conducted?
This trial is being conducted at Pierre-Bénite, France, Pierre-Bénite, France.
Who is sponsoring the NCT07015151 clinical trial?
NCT07015151 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 4,312 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.